Browse diseases

…nhibitors (BTKi) and BCL2 inhibitors (BCL2i) has revolutionised chronic lymphocytic leukaemia (CLL) treatment. CLL typically occurs in older patients, who ha…

…gs were 687,040€.Conclusion and Relevance IBR dose reduction in CLL patients appears to maintain clinical efficacy while improving …

…d a higher risk pathogenetic profile compared with conventional CLL (C-CLL). Although well recognised histologically, peripheral bl…

…erapy has been achieved for acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), and primary mediastinal large B cell lymphoma (PMBCL),…

… population of T cells. The above findings were consistent with CLL/small lymphocytic lymphoma. A positron emission tomography (PET…

…mary statistics from genome-wide association studies (GWASs) of diffuse large B cell lymphoma, follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL) …

…d Methods A prospective analysis was conducted on patients with CLL initiating I+V therapy across four hospitals between May 2023-A…

…fective allogeneic platform for CAR-based immunotherapy in both cancer and autoimmune diseases, providing a strong foundation for furt…

…9) CAR-T cells as well as anti-CD20 bispecific antibodies, with lymphoma cells resulting in CD19 and CD20 antigen loss.Conclusions This …

… only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [Internet]. Bristol M…

…Background Dipeptidyl-peptidase-like protein-6 (DPPX) antibody-associated encephalitis is a rare disease that presents with a triad of central nervous…

…ji J, Lew SQ. The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD). BMJ Case Rep. Publishe…